In December 2014, Janssen entered into a collaboration agreement with us to develop and commercialize MGD011 (CD19 x CD3). We retain co-promotion rights in the U.S. and may elect to fund a portion of late-stage clinical development in exchange for a U.S. and Canada profit share. Learn more
Collaborations have been a critical part of MacroGenics’ growth strategy and will continue to be an emphasis for our future growth strategy. To date, the company has developed significant alliances with leading pharmaceutical and biotechnology companies that enable us to drive forward our proprietary programs, while retaining significant value in the downstream potential of our partnered programs.
The company is actively exploring alliances that complement our expertise in biologics product development with important scientific, clinical and business capabilities. These alliances may incorporate our various technology platforms, product candidates and biologic product development capabilities.
MacroGenics’ Collaboration Partners
In May 2014, Takeda entered into a collaboration agreement to develop and commercialize MGD010, a Dual-Affinity Re-Targeting, or DART® molecule that simultaneously targets CD32B and CD79B, which are two B-cell surface proteins. MGD010 is currently being studied in a Phase 1 trial in healthy volunteers. Learn more
In September 2014, Takeda entered into a second collaboration agreement to develop and commercialize up to four DART product candidates directed against jointly selected target pairs. Learn more
In both collaborations with Takeda, MacroGenics retains co-promotion rights in the U.S. and may elect to fund a portion of Phase 3 clinical development in exchange for a North American profit share.
In January 2013, MacroGenics entered into a license agreement with Gilead Sciences for the development and commercialization of DART products directed at up to four undisclosed targets. Learn more
Under the terms of the September 2012 agreement, MacroGenics retains full development and commercialization rights to three oncology DART molecules in North America, Japan, Korea and India, while Servier has an option to obtain an exclusive license covering the rest of the world. Servier has exercised this option with respect to MGD006 and still retains its options with respect to MGD007 and one other program. Learn more
In October 2010, MacroGenics entered into a global research collaboration and license agreement with Pfizer to discover, develop and commercialize DART products directed at two undisclosed cancer targets. These DART proteins will be used to redirect the body’s cell-destroying, immune effector cells against tumor cells. Learn more
Boehringer Ingelheim entered into a global alliance to discover, develop and commercialize antibody-based therapeutics which may span multiple therapeutic areas. These drug candidates will be based on our DART platform and will be directed against up to ten combinations of molecular targets. Learn more
In July 2010, Green Cross entered into a collaboration agreement with MacroGenics for the development and exclusive commercialization of margetuximab in South Korea.
In September 2015, MacroGenics entered into a contract with the National Institute of Allergy and Infectious Diseases to perform product development and to advance DART product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with HIV infection (contract no. HHSN272201500032C). Learn more